Brought to you by 
Alexion will pay $610mm plus earn-outs to buy Enobia
25 Feb 2021
Executive Summary
Public biotech Alexion Pharmaceuticals Inc. is acquiring closely held Enobia Pharma Inc. (developing enzyme replacement therapies for bone and metabolic disorders) for $610mm in cash and up to $470mm in earn-outs based on regulatory and sales goals.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alexion will pay $610mm plus earn-outs to buy Enobia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice